Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma | Zendy

Vikrant V. Sahasrabuddhe | Zendy; Munira Z. Gunja | Zendy; Barry I. Graubard | Zendy; Britton Trabert | Zendy; Lauren M. Schwartz | Zendy; Yikyung Park | Zendy; Albert R. Hollenbeck | Zendy; Neal D. Freedman | Zendy; Katherine A. McGlynn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma

Author(s) -

Vikrant V. Sahasrabuddhe,

Munira Z. Gunja,

Barry I. Graubard,

Britton Trabert,

Lauren M. Schwartz,

Yikyung Park,

Albert R. Hollenbeck,

Neal D. Freedman,

Katherine A. McGlynn

Publication year - 2012

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djs452

Subject(s) - hepatocellular carcinoma , medicine , nonsteroidal , chronic liver disease , drug , inflammation , gastroenterology , liver disease , disease , cirrhosis , pharmacology

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce chronic inflammation and risk of many cancers, but their effect on risk of hepatocellular carcinoma (HCC) and death due to chronic liver disease (CLD) has not been investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research